This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E23.0 (Kallmann syndrome) | OMIM: 308700 (KAL1), 147950 (FGFR1), 244200 (PROKR2) and many others | Special Copayment Reduction: V165 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Hypogonadotropic hypogonadism with anosmia, KAL1 deficiency, Olfactogenital syndrome, De Morsier syndrome |
| C. Adult onset | Likelihood of first onset in adulthood high — although congenital, it often leads to a first medical visit in late childhood/adolescence to early adulthood in the form of delayed or absent puberty; the loss of smell is congenital, but many patients are unaware of it. |
| 1. History | 1856, Maestre de San Juan reported a case with anosmia and gonadal hypoplasia → 1944, Franz Josef Kallmann systematically described hereditary familial cases → 1989, cloning of the KAL1 gene (Xp22.3). |
| 2. Causes | Failure of migration of GnRH neurons originating from the olfactory placode. Causative genes: KAL1 (anosmin-1), FGFR1, PROKR2, PROK2, CHD7, FGF8, WDR11 and many others. |
| 3. Genetics | High genetic heterogeneity. X-linked (KAL1, Xp22.3), autosomal dominant (FGFR1, FGF8, CHD7), autosomal recessive (PROKR2, PROK2) and oligogenic forms reported. |
| 4. General epidemiology | Incidence about 1/10,000 (males) to 1/50,000 (females). About 4–5 times more common in males. Kallmann syndrome accounts for about 50–60% of all hypogonadotropic hypogonadism. |
| 5. Pathophysiology | Failure of embryonic GnRH neuron migration from the nasal placode → hypothalamus → GnRH secretion deficiency → absence of LH and FSH → failure of gonadal development and sex hormone secretion. Accompanied by aplasia of the olfactory bulb. |
| 6. Symptoms | Anosmia or hyposmia, absent or delayed puberty, amenorrhea, infertility, erectile dysfunction and decreased libido, micropenis and cryptorchidism (male newborns). May be accompanied by bimanual synkinesis. |
| 7. Signs | Lack of sexual maturation (poor testicular/breast development, absence of pubic and axillary hair), extremely low gonadotropins (FSH, LH), low sex hormones (estradiol, testosterone), aplasia or hypoplasia of the olfactory bulb on MRI. |
| 8. Screening | Olfactory function testing in males and females with delayed puberty → measurement of FSH, LH and estradiol/testosterone → pituitary MRI (including assessment of the olfactory bulb). |
| 9. Diagnosis | Confirmation of hypogonadotropic hypogonadism + abnormal olfactory function + aplasia of the olfactory bulb on MRI + identification of the causative gene (molecular genetic testing). GnRH stimulation test, clomiphene test. |
| 10. Treatment | Induction of gonadal development: males — testosterone/hCG+FSH, females — estrogen-progestin; when pregnancy is desired, GnRH pump or gonadotropin injections to induce ovulation and spermatogenesis. |
| 11. Prognosis | Sexual maturation and pregnancy possible with hormone therapy. Spontaneous recovery in about 10–20% (reversible KS). Anosmia cannot be treated. Long-term management of osteoporosis and cardiovascular risk needed. |
| 12. Prevention | Genetic counseling and family testing. Early surgery for cryptorchidism. Early detection through olfactory function assessment in males and females with delayed puberty. Prevention of osteoporosis and cardiovascular complications by minimizing the duration of hormone deficiency. |
| 13. References | Kallmann FJ, Schoenfeld WA, Barrera SE. The genetic aspects of primary eunuchoidism. 1944 … and 9 other papers |
The history of Kallmann syndrome dates back to the mid-19th century. In 1856, the Spanish physician Aureliano Maestre de San Juan first described a case in which anosmia and gonadal hypoplasia occurred together. However, this observation did not draw much attention from the medical community at the time. Later, in 1914, the Spanish neurologist Salvador de Morsier published neuroanatomical studies suggesting a connection between the olfactory bulb and the hypothalamic-pituitary reproductive axis, and in some literature the disease is also called 'De Morsier syndrome'.
The systematic clinical-genetic description of this disease was made by Franz Josef Kallmann (1897–1965), a German-American psychiatrist and geneticist. In his 1944 paper published in the American Journal of Mental Deficiency, "The genetic aspects of primary eunuchoidism", Kallmann analyzed about 40 patients from 12 families and first systematically described that anosmia and hypogonadism are transmitted together genetically. He pointed out that the disease follows modes of inheritance including X-linked inheritance and occurs at a much higher frequency in males. The scientific community subsequently named this complex syndrome after him as 'Kallmann syndrome'.
With advances in molecular genetics, in 1989–1991 two research teams (Franco et al. and Legouis et al.) independently succeeded in cloning KAL1 (located at X chromosome p22.3, encoding the anosmin-1 protein), the causative gene of Kallmann syndrome. This was the first achievement in elucidating the molecular basis of Kallmann syndrome and became the starting point for an extensive search for causative genes. In 2003, FGFR1 (also called KAL2) was identified as the second causative gene, revealing the genetic basis of autosomal dominant Kallmann syndrome, and more than 20 related genes have since been additionally identified.
Research on the embryologic origin and migration pathway of GnRH neurons was carried out in 1989 by Schwanzel-Fukuda and Pfaff. They first described the process by which GnRH neurons originating from the nasal placode migrate along the olfactory nerves to the base of the brain, and proposed that failure of this migration in Kallmann syndrome results in GnRH deficiency and abnormal development of the olfactory organs at the same time. This discovery provided an integrated theory that clearly explains how the two key features of Kallmann syndrome — anosmia and hypogonadism — are linked by a common developmental mechanism. Kallmann syndrome is currently classified internationally as a subtype with olfactory abnormalities within the category of congenital hypogonadotropic hypogonadism (CHH) due to GnRH deficiency.
The root cause of Kallmann syndrome is failed migration of GnRH neurons in embryonic life. GnRH neurons originate early in embryonic life from the nasal placode, migrate along the vomeronasal nerve to the base of the brain and finally settle in the hypothalamus, where they become responsible for pulsatile GnRH secretion. Many molecular signals and cell adhesion molecules are involved in this migration process, and when pathogenic variants occur in the genes encoding them, GnRH neurons fail to reach the hypothalamus. As a result, global dysfunction of the reproductive axis occurs, proceeding from GnRH deficiency → reduced LH and FSH secretion → absence of gonadal stimulation → impaired sexual development.
At the same time, the development of the olfactory bulb and olfactory tract is also closely linked to GnRH neuron migration, so when migration fails, the olfactory bulb does not form or is severely hypoplastic, accompanied by congenital anosmia or hyposmia. This is why the two key clinical hallmarks of Kallmann syndrome are inseparably linked.
The main genes identified to date as causes of Kallmann syndrome are as follows. KAL1 (Xp22.3, also written ANOS1): encodes the anosmin-1 protein. Anosmin-1 is an extracellular matrix component (heparan sulfate proteoglycan binding) that aids migration of GnRH neurons and olfactory nerve fibers. X-linked recessive inheritance. FGFR1 (8p11.23): fibroblast growth factor receptor 1. Autosomal dominant. Its ligand FGF8 is also involved. PROKR2·PROK2: prokineticin receptor 2 and ligand 2. Autosomal recessive or dominant. Involved in both olfactory bulb development and GnRH neuron migration. CHD7: also associated with CHARGE syndrome but can present as isolated Kallmann syndrome. Additional genes such as WDR11, NSMF (NELF), HS6ST1, SEMA3A, SEMA7A, SOX10 and TUBB3 have been reported. The proportion of Kallmann syndrome explained by currently known gene variants is about 30–40% of the total, and in the remaining 60–70% the causative gene has not yet been identified.
Oligogenic inheritance is observed in many patients with Kallmann syndrome; this refers to cases in which the phenotype is not fully explained by a single gene variant alone and is determined by a combination of rare variants in two or more genes. This complex mode of inheritance contributes to explaining the phenotypic diversity and incomplete penetrance of Kallmann syndrome.
Kallmann syndrome is a genetically heterogeneous disease, with more than 20 causative genes reported to date. All four types of inheritance exist: X-linked recessive, autosomal dominant, autosomal recessive and oligogenic.
X-linked inheritance: the form caused by KAL1 (ANOS1) gene variants is representative. The KAL1 gene is located at band 22.3 of the short arm of the X chromosome (Xp22.3), and various pathogenic variants including deletions, frameshift, nonsense and missense variants have been reported. The X-linked form is expressed in males (XY) as hemizygous and shows a severe phenotype, while female carriers are mostly asymptomatic or show only mild olfactory abnormalities. Bilateral cryptorchidism and renal developmental anomalies (renal agenesis) frequently accompany KAL1 variants.
Autosomal dominant inheritance: forms caused by FGFR1 (KAL2), FGF8, CHD7, WDR11 and SEMA3A variants. FGFR1, a receptor of the FGF signaling system, is essential for GnRH neuron migration and olfactory bulb formation. This form is characterized by incomplete penetrance and variable expressivity, and even within the same family a broad spectrum is observed, from typical Kallmann syndrome to normal phenotypes and forms with only hyposmia. Non-reproductive phenotypes such as cleft palate, dental agenesis and finger and toe anomalies may accompany it.
Autosomal recessive inheritance: PROKR2, PROK2, GNRHR, GNRH1, TAC3 and TACR3 variants are representative. These genes are mainly involved in GnRH neuron migration (PROKR2/PROK2) or in the mechanisms of GnRH secretion and reception themselves (GNRHR, GNRH1), and PROKR2/PROK2 variants in particular also overlap with normosmic CHH, which presents only with hypogonadotropic hypogonadism without olfactory abnormalities. PROKR2 and FGFR1 variants have also been reported relatively commonly in a Korean cohort of patients with Kallmann syndrome.
Clinically and genetically, it is important that although next-generation sequencing (NGS)-based panel testing has greatly increased the rate of identifying causative genes, the causative gene is still unidentified in about 60% of patients. In addition, because phenotypic differences are large even among family members with the same gene variant, integrated interpretation of genetic test results and the clinical phenotype is essential. When there is a family history, offering genetic testing and genetic counseling to asymptomatic family members is recommended.
The prevalence of Kallmann syndrome worldwide is estimated at about 1/10,000 in males and about 1/50,000 in females, occurring about 4–5 times more frequently in males. This sex difference is partly because the X-linked form (KAL1 variants) is expressed hemizygously in males, but a male predominance is also observed in autosomal forms, so it is not fully explained. Kallmann syndrome accounts for about 50–60% of all hypogonadotropic hypogonadism (HH), somewhat more than normosmic HH without olfactory abnormalities.
Incidence studies have not reported marked differences by race or region, suggesting that the various causative genes are evenly distributed in populations worldwide. However, the frequency of specific gene variants may differ by ethnicity. For example, PROKR2 variants are reported in both European and East Asian patient cohorts, but certain homozygous variants (e.g., L173R) are observed at higher frequency in some populations.
In Korea, accurate prevalence data are lacking, but rare disease Special Copayment Reduction registration records and a few domestic cohort studies confirm that it accounts for an important proportion of the causes of delayed puberty and infertility in adult men. In a domestic study analyzing patients with hypogonadotropic hypogonadism, a considerable proportion had accompanying olfactory abnormalities and were diagnosed with Kallmann syndrome. The age at diagnosis is mostly the late teens to twenties, and patients often visit endocrinology or urology with absent puberty or infertility as the chief complaint.
Some male patients present with cryptorchidism or micropenis in the newborn period and are diagnosed in childhood, but overall, adult patients first presenting with delayed puberty or infertility make up the majority. Female patients are often first identified with primary amenorrhea, and because olfactory abnormalities are often not subjectively recognized, diagnosis may be further delayed. Systematically performing olfactory function testing in males with delayed puberty can increase the rate of early diagnosis.
The pathogenesis of Kallmann syndrome can be summarized as failed migration of GnRH neurons in embryonic life and the accompanying abnormal development of the olfactory bulb. In normal development, GnRH neurons originate at around 6–8 weeks of gestation from the nasal placode (a specialized region of the nasal mucosa) and migrate along the olfactory nerve bundles, particularly the vomeronasal nerve/terminal nerve, through the cribriform plate to the base of the forebrain. The migrated GnRH neurons finally settle in the preoptic area and mediobasal region of the hypothalamus and begin pulsatile GnRH secretion.
Cell adhesion molecules, growth factors and chemotactic signals act in combination in this migration process. Anosmin-1 (the KAL1 gene product) is an extracellular matrix component that binds heparan sulfate proteoglycan and promotes the movement of GnRH neurons. FGFR1 is the receptor for FGF8 and is required for both olfactory bulb development and GnRH neuron migration. PROK2/PROKR2 play a role in olfactory bulb formation and in the final stage of GnRH neuron migration. When a loss-of-function variant occurs in any one of these molecules, GnRH neurons cannot enter the brain and remain abnormally in the nasal cavity or at the base of the frontal lobe.
Failure of GnRH neurons to reach the hypothalamus means that GnRH secretion itself does not occur, which leads to a complete absence of the signal stimulating pituitary LH and FSH secretion. As a result, the 'minipuberty' that should normally occur in fetal and neonatal life does not occur, and in boys normal development of the penis and testes is suppressed, resulting in micropenis and cryptorchidism. At puberty, too, the absence of LH and FSH secretion means there is no gonadal stimulation, so puberty does not occur. On the olfactory bulb side, when the molecular signals guiding GnRH neuron migration are lacking, olfactory bulb formation is impaired at the same time, resulting in aplasia or hypoplasia of the olfactory bulb that can be seen on MRI.
One important feature is that spontaneous recovery (reversal of hypogonadism) is observed in about 10–20% of patients with Kallmann syndrome. This is presumed to result from incomplete failure of GnRH neuron migration, functional recovery of residual GnRH neurons, or the development of alternative neural pathways, but the exact mechanism has not yet been clearly elucidated. This spontaneous recovery is confirmed by sustained gonadal function after discontinuation of hormone therapy, and follow-up without sex hormone replacement for at least 3 months after treatment to assess spontaneous GnRH secretion is recommended.
The clinical symptoms of Kallmann syndrome fall broadly into abnormalities of the olfactory system and abnormalities of the reproductive system. Anosmia or hyposmia is the defining feature of this disease; it is congenital, but patients very often perceive the absence of smell as normal and do not report it as a chief complaint. Clinicians should therefore actively assess olfactory function. Taste abnormalities may accompany it, but they present as reduced perception of flavor, which depends on smell, rather than impaired taste reception itself (taste bud function).
Reproductive symptoms in males include absent or delayed puberty (no increase in testicular volume, penile development, pubic hair growth or voice change by age 15–16), micropenis (neonatal period), cryptorchidism (bilateral or unilateral), azoospermia, erectile dysfunction and decreased libido, gynecomastia (a feminine body shape due to fat distribution without pubertal development), a high-pitched voice (no voice change), and eunuchoid body habitus (lower limbs long relative to upper limbs and arm span greater than height). In females, the main symptoms are primary amenorrhea, poor breast development, absence of female-pattern pubic hair development, and vaginal dryness.
Among associated non-reproductive features, bimanual synkinesis (mirror movements) is observed at a specifically high frequency of about 80% in patients with KAL1 variants. This is a phenomenon in which, when one hand moves, the opposite hand involuntarily follows. In addition, cleft palate, dental developmental abnormalities, hearing abnormalities, renal developmental abnormalities (single kidney or renal agenesis), color vision abnormalities (color blindness), cerebellar ataxia, and binocular gaze palsy (oculomotor defect) may accompany some genetic subtypes. Delayed bone age, decreased bone density and anemia appear as secondary consequences of long-term sex hormone deficiency.
On physical examination, objective findings of delayed sexual maturation are prominent. In males, if testicular volume is less than 4 mL with micropenis (stretched penile length below 2.5 standard deviations for adults) or cryptorchidism (one or both testes not descended into the scrotum), hypogonadotropic hypogonadism, including Kallmann syndrome, must be considered in the differential. Absence or markedly poor development of pubic and axillary hair (Tanner stage I), along with weak muscle development and a lower-limb-predominant eunuchoid habitus, is observed. In females, absence of breast development (Tanner stage I) and immature size of the uterus and ovaries on ultrasound are found.
Laboratory findings show serum LH and FSH concentrations that are extremely low (prepubertal levels) or below the lower limit of detection. Serum testosterone (males) or estradiol (females) also typically shows extremely low values. Serum prolactin and other pituitary hormones (ACTH, TSH, GH axis) are normal, which is an important point of differentiation from panhypopituitarism. Serum inhibin B and anti-Müllerian hormone (AMH) are decreased, but they are not essential diagnostic markers. Bone densitometry (DXA) frequently shows osteopenia for age.
On pituitary MRI (special sequences including assessment of the olfactory bulbs), the finding of aplasia or marked hypoplasia of the olfactory bulbs is the key imaging sign of Kallmann syndrome. Normal pituitary morphology and hypothalamic structures are confirmed, which differentiates it from secondary hypogonadism due to pituitary tumors or craniopharyngioma. Olfactory testing (standardized tools such as UPSIT and Sniffin' Sticks) confirms anosmia or severe hyposmia.
Screening for Kallmann syndrome is performed in two directions based on clinical suspicion. First, in the neonatal and infant period, it is possible by assessing for minipuberty (a transient rise in FSH, LH and testosterone at 1–6 months of age) in boys found to have bilateral cryptorchidism or micropenis. If serum LH, FSH and testosterone are all extremely low at 2–3 months of age, hypogonadotropic hypogonadism is strongly suggested.
Second, in adolescents with delayed puberty (no secondary sexual characteristics by age 14 in males and age 13 in females), an endocrine evaluation including olfactory function testing is performed. If standardized olfactory function tests (Sniffin' Sticks test, Connecticut Chemosensory Clinical Research Center Test, etc.) confirm anosmia or severe reduction, a detailed evaluation including measurement of serum LH, FSH and sex hormones is carried out. Differentiation from simple delayed puberty (constitutional delay of growth and puberty, CDGP) is clinically important; CDGP is distinguished in that puberty is merely delayed, olfactory function is normal, and there is often a family history of delayed puberty.
In high-risk groups with a family history (first-degree relatives of patients with Kallmann syndrome), regular olfactory function testing and measurement of baseline serum gonadal hormones are recommended. In addition, if a renal developmental abnormality (single kidney) is found on fetal anomaly ultrasound during pregnancy, family screening for Kallmann syndrome (the KAL1 variant-related form) may be considered.
The diagnosis of Kallmann syndrome is made by a combination of four elements: ① biochemical confirmation of hypogonadotropic hypogonadism, ② objective demonstration of olfactory dysfunction, ③ confirmation of olfactory bulb abnormalities on MRI, and ④ confirmation of a causative gene variant. Not all of these elements need to be met, and the diagnostic criteria are applied differently depending on the clinical context.
Biochemical diagnosis: confirmation of extremely low serum LH, FSH and testosterone (males) or estradiol (females). The other anterior pituitary hormone axes (TSH, ACTH, GH, prolactin) are normal. An absent or very weak response on the GnRH stimulation test (measurement of LH and FSH after GnRH 100 μg IV) supports Kallmann syndrome (although in some, the response recovers after prolonged stimulation). A prolonged GnRH analog stimulation test (leuprolide acetate stimulation test) is also sometimes used to differentiate it from delayed puberty.
Olfactory testing: olfactory function is assessed objectively using Sniffin' Sticks (Burghardt, Germany), UPSIT (University of Pennsylvania Smell Identification Test), or other standardized olfactory identification, threshold and discrimination tests. A composite TDI (threshold-discrimination-identification) score below 30 is judged as olfactory dysfunction.
MRI diagnosis: in addition to pituitary MRI, high-resolution T2 or FLAIR sequences optimized for assessment of the olfactory bulbs must be included. Reduced volume or absence of the olfactory bulbs and absence of the olfactory tracts are the main findings. Normal pituitary morphology and a normal hypothalamus are confirmed to exclude organic causes.
Genetic testing: NGS with a CHH gene panel including KAL1, FGFR1, FGF8, PROKR2, PROK2, CHD7, WDR11, etc. is performed. Molecular diagnosis is used for confirming the disease, genetic counseling, family testing and predicting some phenotypes, but it has little direct impact on treatment decisions. Because the gene variant identification rate is about 30–40%, a clinical diagnosis is not excluded even if no variant is found on genetic testing.
The treatment goals for Kallmann syndrome are threefold: ① induction of sexual development, ② maintenance of bone density and metabolic health, and ③ restoration of reproductive function when needed. Treatment strategies are applied differently depending on the patient's sex, age and desire for pregnancy.
Induction of sexual development in males: for pubertal induction, intramuscular injection of testosterone enanthate or undecanoate, or transdermal application of testosterone gel, is the standard treatment. Starting at a low dose initially (e.g., enanthate 25–50 mg/2 weeks IM) and gradually increasing to the adult dose over 2–3 years mimics the normal course of puberty. If cryptorchidism is present, hCG (human chorionic gonadotropin) injections may help testicular descent and increase in size, and surgical orchiopexy is sometimes needed.
Induction of spermatogenesis in males desiring pregnancy: hCG (1,500–2,000 IU, 2–3 times a week subcutaneously or intramuscularly) is given alone, or if sufficient spermatogenesis is not achieved, recombinant FSH (75–150 IU, 3 times a week) is added. Alternatively, there is a physiological method of stimulating the pituitary using a GnRH pump (subcutaneous pulsatile infusion of GnRH 5–20 μg at 90-minute intervals). With successful treatment, spermatogenesis is restored and pregnancy becomes possible in more than 80% of patients.
Treatment in females: cyclic estrogen-progestin therapy is used to induce and maintain pubertal development and protect bone density. When pregnancy is desired, ovulation induction with FSH+LH or FSH alone, or ovulation induction using a GnRH pump, is possible. Relatively high pregnancy success rates have been reported. Patients are educated that olfactory function is not restored by any treatment.
In all patients, bone density monitoring (DXA), vitamin D and calcium supplementation, and recommendation of regular weight-bearing exercise are needed. When micropenis or cryptorchidism is identified in a newborn boy, starting hCG or testosterone treatment early is beneficial for penile growth and testicular development.
The prognosis of Kallmann syndrome is generally good, and with appropriate hormone therapy, normal social activity and restoration of reproductive function are possible. Testosterone or estrogen replacement therapy has been proven effective in normalizing secondary sexual characteristics, restoring sexual function, and improving bone density and cardiovascular markers.
Regarding reproductive function, in about 70–80% of male patients treated with hCG+FSH or a GnRH pump, spermatogenesis is restored and pregnancy is possible either naturally or through assisted reproductive technology. The longer the prior period of testosterone-only treatment, the longer induction of spermatogenesis may take, but most eventually succeed. Many cases of successful pregnancy after ovulation induction treatment have also been reported in female patients.
Characteristically, spontaneous reversal is observed in about 10–20% of patients with Kallmann syndrome. This is a phenomenon in which spontaneous gonadotropin secretion and sex hormone production are maintained even after hormone therapy is discontinued after being continued for several years. This reversible form has been suggested to be associated particularly with FGFR1 or PROKR2 variants, but it can occur with any genotype. It is therefore recommended that hormone therapy be stopped at least once during treatment to reassess gonadal function.
As long-term complications, if hormone therapy is started late, the risk of osteoporosis persists, and regular DXA follow-up is needed. In some patients with accompanying growth hormone deficiency, excess body fat, muscle loss and cardiometabolic risk may increase. Anosmia is not restored by any treatment, leaving permanent limitations in cooking, detecting gas leaks and recognizing spoiled food. Psychologically, adolescent self-image problems due to delayed sexual development and infertility-related stress can affect quality of life, so referral to psychological support services is recommended.
Kallmann syndrome is a congenital genetic disease, so primary prevention is limited, but reduction of genetic risk and prevention of complications through early detection are possible. Genetic counseling is a key service for families of patients with Kallmann syndrome. In particular, in the X-linked (KAL1) form, female carriers transmit the disease to sons with a 50% probability, so information should be provided on family genetic testing and prenatal diagnosis (molecular genetic testing via chorionic villus sampling or amniocentesis). In the autosomal dominant form, there is a 50% risk of transmission from an affected parent to a child.
Early detection and treatment are key to preventing complications. When bilateral cryptorchidism or micropenis is found in a newborn boy, endocrinology and urology consultation should be carried out immediately to evaluate for hypogonadotropic hypogonadism. Early hCG treatment (at 3–6 months of age) is beneficial for penile growth and preservation of testicular function, and reduces the risk of infertility due to cryptorchidism. In adolescents with delayed puberty, early diagnosis through systematic evaluation including olfactory testing followed by timely initiation of hormone therapy can minimize bone density loss, eunuchoid habitus and psychological complications.
To prevent long-term complications, bone density monitoring, vitamin D and calcium supplementation, recommendation of weight-bearing exercise and management of cardiovascular risk factors are essential in all patients after diagnosis. Assessment for spontaneous recovery after treatment discontinuation is performed regularly, and in patients with confirmed spontaneous recovery, it is monitored whether gonadal function is maintained without exogenous hormone replacement. It is also important to provide, through patient education, lifestyle guidance on coping with safety risks due to anosmia (gas leaks, food poisoning).